Biography
- Division:
- Division of Translational and Clinical Sciences – DTCS
- Review Branch:
- Cancer Diagnosis, Prevention & Therapeutics – CDPT
- Study Section:
- Cancer Diagnostics and Treatments (CDT) SBIR/STTR SEP – CDPT13
Dr. Asifa Haider holds a Ph.D. in molecular pharmacology from New York Medical College, US, and is a licensed pharmacist from ETH-Zurich, Switzerland. She completed a postdoctoral fellowship at Rockefeller University, NY. She applied pharmacogenomics to evaluate the role of immune microenvironments in preclinical and clinical oncology and autoimmune studies. During her career in biotech/pharma, her focus has been to understand immune pathways and molecular mechanisms underlying diseases and developing molecular biomarkers for early detection, risk assessment, diagnosis, and therapeutic development. She supported early- and late-phase clinical trials as principal scientist, scientific/project manager, and translational biomarker leader in small businesses and large pharmaceutical companies, including Novartis, Sanofi, and Cellectis Inc. As a translational scientist, she has more than 15 years of experience in implementing and developing strategies for immune oncology, small molecules, antibodies, autologous and allogeneic Chimeric Antigen Receptor T cells (CAR T), biomarkers, and companion diagnostics.
